KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
Gerard A. Silvestri MD, MS
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
November 9, 2026
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP
Tiffany Traina, MD
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.